Hoffmann-la Roche Inc.

Lts Lohmann Therapie-systeme Ag

Other

Bristol-myers Squibb Compnay

Boehringer Mannheim Gmbh

Engmab Ag

F. Hoffmann-la Roche Ag

Roche Glycart Ag

Engmab Sarl

Engmab Beta Holdings LLC

Wolfgang Schaefer

Christian Klein

Joerg Thomas Regula

Sabine Imhof-Jung

Michael Molhoj

Konrad Honold

Juergen Michael Schanzer

Pablo Umana

Stefan Scheiblich

Guy Georges

Stefan Klostermann

Hubert Kettenberger

Petra Rueger

Ekkehard Moessner

Marina Bacac

Werner Scheuer

Oliver Ast

Claudio Sustmann

Ulrich Brinkmann

Ulrich Goepfert

Laurent Lariviere

Harald Duerr

Ralf Hosse

Birgit Bossenmaier

Anita Kavlie

Monika Baehner

Stefan Seeber

Klaus Kaluza

Klaus-Peter Kuenkele

Michael Schraeml

Dieter Heindl

Christos Tsaklakidis

Walter-Gunar Friebe

Pablo Umaña

Christiane Neumann

Manfred Schwaiger

Sebastian Fenn

Samuel Moser

Peter Schwarz

Birgit Masjost

Markus Thomas

Remko Griep

Tanja Fauti

Detlev Neuland

Lydia Jasmin Hanisch

Tilman Schlothauer

Thomas U Hofer

Michael Gerg

Anne Freimoser-Grundschober

Klaus Mayer

Richard Engh

Ulrich Tibes

Klaus Strein

Minh Diem Vu

Ramona Murr

Sabine Jung-Imhof

Kay-Gunnar Stubenrauch

Peter Bruenker

Bodo Asmussen

Matthias Koerner

Stefan Dengl

Ulrike Reiff

Adelbert Grossmann

Edgar Voss

Guido Hartmann

Stefan Weigand

Matthias Rueth

Gerhard Niederfellner

Michael Tacke

Angelika Esswein

Thomas Von Hirschheydt

Johannes Auer

Tim Sattelkau

Rebecca Croasdale

Sylvia Herter

Maximiliane Koenig

Hubert Hertenberger

Rebecca Croasdale-Wood

Joerg-Thomas Regula

Richard John Buick

Irene Kolm

Hanshermann Franke

Christiane Jaeger

Carmen Peess

Rudi Brathuhn

Lydia Jasmin Duerner

Joerg Thomas

Jane Paul

Carl Roeschlaub

Alan Whittle

Remko Albert Griep

Anne Freimoser-grundschober

Klaus-peter Kuenkele

Herein are provided bispecific anti-human A-beta/human transferrin receptor antibodies and methods of using the same.

Bispecific anti-human A-beta/anti-human transferrin receptor antibodies

The present invention relates to antibodies and Fc-region fusion polypeptides which are asymmetrically modified with respect to their Fc-receptor, especially their FcRn, and methods of using the same.

Fc-receptor binding modified asymmetric antibodies and methods of use

Herein are provided bispecific anti-human CD20/human transferrin receptor antibodies and methods of using the same.

Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use

The present invention relates to multispecific antibodies comprising at least three antigen binding sites wherein the third binding site is disulfide stabilized by introduction of cysteine, method for their production, pharmaceutical compositions containing said antibodies and uses thereof.

Multispecific antibodies

The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.

Bispecific antibodies against CD3EPSILON and ROR1

The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific HER2 antibodies and methods of use

Herein are provided bispecific anti-human A-betalhuman transferrin receptor antibodies and methods of using the same.

Bispecific anti-human A-beta/human transferrin receptor antibodies and methods of use

Herein is reported a method for the humanization of non-human antibodies using a structure-based scoring matrix. With the scoring matrix it is possible to determine (the requirement for and) the suitability of specific (back)mutations of amino acid residues at defined positions of a selected human germline sequence. The scoring matrix takes into account the topology, the three-dimensional structure and the interactions of the respective residue and change. Thereby the influence on antigen binding of a specific amino acid residue change can be determined.

Three-dimensional structure-based humanization method

The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Bispecific antigen binding proteins

Herein is reported a polypeptide-polynucleotide-complex as therapeutic agent and its use as tool for the targeted delivery of an effector moiety. The polynucleotide part of the complex is essentially resistant to proteolytic and enzymatic degradation in vivo. Additionally the polypeptide part specifically binds to a compound or structure such as a tissue or organ, a process or a disease. Thus, one aspect as reported herein is a polypeptide-polynucleotide-complex comprising a) a polypeptide specifically binding to a target and conjugated to a first member of a binding pair, b) a polynucleotide linker conjugated at its first terminus to the second member of the binding pair, and c) an effector moiety conjugated to a polynucleotide that is complementary to at least a part of the polynucleotide linker.

Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Bispecific T cell activating antigen binding molecules

Herein is reported the use of an antibody comprising an Fc-region with abolished FcRn binding for the transport of a soluble receptor ligand from the eye over the blood-ocular-barrier into the blood circulation.

Human FcRn-binding modified antibodies and methods of use

The present invention relates to nucleic acids which encode the heavy chains and light chains of a novel domain exchanged, bivalent, bispecific antibody, and vectors comprising the same.

Bivalent, bispecific antibodies

Growing community of inventors

Mannheim, Germany

Wolfgang Schaefer